

Cutaneous and acral melanoma cross-OMICs reveals prognostic cancer drivers associated with pathobiology and ultraviolet exposure

Anna Luiza Silva Almeida Vicente^{1,2*}, Alexei Novoloaca², Vincent Cahais², Zainab Awada², Cyrille Cuenin², Natália Spitz², André Lopes Carvalho¹, Adriane Feijó Evangelista¹, Camila Souza Crovador¹, Rui Manuel Reis^{1,3,4}, Zdenko Herceg^{2†}, Vinicius de Lima Vazquez^{1,5†}, Akram Ghantous^{2†*}

¹Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, São Paulo, Brazil

²International Agency for Research on Cancer (IARC), Lyon, France

³Life and Health Sciences Research Institute (ICVS), Health Sciences School, University of Minho, Braga, Portugal

⁴ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal

⁵Department of Surgery – Melanoma and Sarcoma, Barretos Cancer Hospital, Barretos, São Paulo, Brazil

†These authors jointly supervised this work

*Correspondence to Akram Ghantous, PhD, Epigenomics and Mechanisms Branch, International Agency for Research on Cancer (IARC), 150 Cours Albert Thomas, 69008 Lyon, France

E-mail: GhantousA@iarc.fr

*Correspondence to Anna Luiza Vicente, Molecular Oncology Research Center, Barretos Cancer Hospital, Rua Antenor Duarte Villela, 1331, 14784-400, Barretos, Brazil

E-mail: annaluizaalmeida@hotmail.com

Key words: melanoma, cutaneous, acral, ultraviolet radiation, pathology, DNA methylome, mutation signatures, transcriptome, cross-OMICs, cancer driver genes

1 **Abstract**

2

3 Ultraviolet radiation (UV) is causally linked to cutaneous melanoma, yet the underlying epigenetic

4 mechanisms, known as molecular sensors of exposure, have never been characterized in clinical

5 biospecimen. Here, we integrate clinical and epigenome (DNA methylome), genome and

6 transcriptome profiling of 112 cutaneous melanoma from two multi-ethnic cohorts. We identify

7 UV-related alterations in regulatory regions and immunological pathways, with multi-OMICS

8 cancer driver potential affecting patient survival. *TAPBP*, the top gene, is critically involved in

9 immune function and encompasses several UV-altered methylation sites that were validated by

10 targeted sequencing, providing cost-effective opportunities for clinical application. The DNA

11 methylome also reveals non UV-related aberrations underlying pathological differences between

12 the cutaneous and 17 acral melanomas. Unsupervised epigenomic mapping demonstrated that

13 non UV-mutant cutaneous melanoma more closely resembles acral rather than UV-exposed

14 cutaneous melanoma, with the latter showing better patient prognosis than the other two forms.

15 These gene-environment interactions reveal translationally impactful mechanisms in

16 melanomagenesis.

17

18 **Introduction**

19

20 Melanoma is a neoplasm arising from melanocytes in the skin, mucosa, or uvea¹. It
21 accounts for more than 75% of skin cancer-related deaths though it represents less than 5% of
22 all cutaneous malignancies². The incidence of melanoma has been increasing worldwide³ and
23 this trend has been observed for decades in some populations (e.g. the US)⁴.

24 Epidemiologic studies have highlighted that the strongest risk factors for cutaneous
25 melanoma development are severe sunburns during childhood and intense intermittent ultraviolet
26 (UV) exposure, which consists of UVC (100-280 nm), UVB (290–320 nm) and UVA (320–400
27 nm)⁵. However, there are types of melanoma that arise in body parts protected from direct UV
28 light, and these are acral, mucosal and uveal melanomas. These types represent uncommon
29 cancers, among which the most frequent is the acral melanoma, which occurs on the glabrous
30 skin (the skin of palms of the hands and the soles of the feet) and the subungual area^{6,7}. Even
31 though it is rare in the general population, acral melanoma is the most common melanoma among
32 people with darker skin⁸.

33 The melanoma genome has the highest mutation burden of any cancer and a predominant
34 C>T nucleotide transition signature attributable to UV radiation^{9,10}. Recently, ten mutated UV
35 signature genes were identified in both clinical samples and animal models, and patients
36 harboring the UV mutation signature presented longer disease-free and overall survival¹¹.
37 Although associations between genetic changes and UV exposure have been well characterized,
38 the role of epigenetic modifications induced by UV exposure has never been investigated directly
39 in human melanoma tissues (Supplementary Data 1). Epigenetic mechanisms function as central
40 players in tumorigenesis and as molecular sensors to environmental factors¹². In fact, CpG DNA
41 methylation sites are highly sensitive to UV damage, as evidenced from experimental approaches
42 of UV exposure using cell line and animal models¹³.

43 Furthermore, the DNA methylation profile of acral melanomas is barely characterized,
44 which could be due in part to its scarcity. It is also unclear whether molecular differences between
45 UV-related and non UV-related melanoma types are due to intrinsic pathological characteristics,
46 extrinsic responses to UV exposure or a combination of both. To address such critical research
47 questions in the field, a comparative study encompassing both cutaneous and acral melanomas
48 would represent an important step forward, with particular focus on epigenetic mechanisms as
49 they can function as both sensors to exposures and key determinants of cell identity. The most
50 recent melanoma classification by the World Health Organization (WHO), including the Blue
51 Books by the International Agency for Research on Cancer (IARC), presented evidence based
52 on epidemiologic, clinical, histopathologic and genomic features¹⁴, while not comprising yet
53 epigenomics.

54 We hypothesize that epigenetic alterations, interplaying with transcriptional and mutational
55 events, constitute critical biological mechanisms underpinning intrinsic pathological differences
56 and extrinsic responses to UV exposure in cutaneous and acral melanomas. We perform
57 differential DNA methylome-wide analysis in cutaneous melanoma patients comparing UV-
58 exposed and non UV-exposed melanomas in two independent clinical cohorts, including a sample
59 population from Brazil which encompasses the white and pigmented phenotypes (Figure 1). UV
60 exposure status is predicted from UV mutational signatures derived from whole genome
61 sequencing (WGS) or whole exome sequencing (WES). This is followed by functional genomic,
62 pathway and methylation-expression analysis of the identified DNA methylation alterations,
63 assessment of their cancer driver roles using a multi-OMICs approach, investigation of their effect
64 on patient survival, and validation of the top hits using bisulfite pyrosequencing. The methylome
65 landscape of cutaneous melanoma is then compared to that of acral melanoma to elucidate the
66 relative contributions of intrinsic pathological and extrinsic UV-related differences towards
67 shaping the cancer epigenome of the two major UV-related and non UV-related melanoma types
68 (Figure 1).

69 Results

70 Cross genome-methylome analysis of UV exposure in cutaneous melanoma

71 UV mutation status was predicted in cutaneous melanoma patients using WGS and WES
72 data from Barretos Cancer Hospital (BCH) in the context of International Cancer Genome
73 Consortium (ICGC)-Brazil project and The Cancer Genome Atlas (TCGA) study, respectively
74 (Figure 1). Similar characteristics were observed in the BCH and TCGA cutaneous melanoma
75 patients, including larger proportions of the male sex, white skin phenotype, metastatic tumor
76 type, UV mutation signature, and BRAF molecular group (Table 1). Primary tumors and *BRAF*
77 mutations were relatively more enriched in BCH than in TCGA patients (Table 1, $p = 9.40e-03$, $p =$
78 $3.20e-03$, respectively).

79 We observed that UV-mutant cutaneous melanoma patients have higher melanoma-
80 specific survival relative to non UV-mutant patients in both BCH and TCGA (Figure 2a). In order
81 to investigate whether the DNA methylome functions as a molecular sensor to UV exposure and
82 underlies the difference in survival between UV-mutant *versus* non UV-mutant cutaneous
83 melanoma patients, DNA methylome-wide analysis based on Infinium HumanMethylation450
84 (450K) array was performed in BCH samples and compared with that in the TCGA cohort (the
85 quality control analysis and selection of the appropriate statistical model, including adjustment for
86 potential confounders, are described in the Methods section and Supplementary Data 2-5).

87 In BCH melanomas, of the 2,620 differentially methylated regions (DMRs), 1,541 (58.8%)
88 were hypermethylated and 1,079 (41.2%) were hypomethylated (Figure 2b; Supplementary Data
89 2). A similar proportion of hypermethylated (62.8%; 378 out of 602) and hypomethylated (37.2%;
90 224 out of 602) DMRs was observed in TCGA (Figure 2b; Supplementary Data 6). The enrichment
91 distributions in CpG regulatory or density regions were also similar in both cohorts. Specifically,
92 in CpG regulatory regions, the significant enrichments in both cohorts were those of
93 hypomethylated DMRs in regions 1-5Kb upstream of the transcription start site and of
94 hypermethylated DMRs in promoters, exon/intron boundaries and 5'UTR ($p < 0.001$) (Figure 2c).

95 In CpG density regions, the significant enrichments were those of hyper- or hypo-methylated
96 DMRs in CpG islands or shores ($p < 0.001$) (Figure 2d).

97

98 **The DNA methylome marks UV exposure with effect on immunomodulation**

99 In order to prioritize the top DMRs that distinguish UV-mutant and non UV-mutant
100 cutaneous melanoma patients (Supplementary Data 7-8), we applied the filters described in
101 Supplementary Fig. 1a to focus on DMRs encompassing at least 3 CpGs, with consistent
102 directions of effect, absolute effect sizes $\geq 10\%$, and not enriched in single nucleotide
103 polymorphisms (SNPs). The resultant methylome map distinctly clustered UV-mutant from non
104 UV-mutant patients in both BCH and TCGA (Figure 3a). In the BCH cohort, cluster C1 (as defined
105 by Euclidean distance) was fully occupied by non UV-mutant samples (Figure 3a) and exhibited
106 a DNA methylation profile that was visually distinct, with an upper hypermethylation (red) stretch
107 and a lower hypomethylation (blue) stretch, relative to the other clusters. Even if C1 is merged
108 with the adjacent cluster C2, the non UV-mutant patients remain statistically enriched in this
109 combined cluster ($p\text{-value} = 1.95e\text{-}03$), which now encompasses almost all non UV-mutants
110 analyzed. A similar pattern was observed in the TCGA cohort. Cluster C3 was fully occupied by
111 non UV-mutant samples and was visually distinct, exhibiting again an upper hypermethylation
112 (red) stretch and a lower hypomethylation (blue) stretch, relative to the other clusters. Even if C3
113 is merged with the adjacent cluster C4, the non UV-mutant patients remain statistically enriched
114 in this combined cluster ($p\text{-value} = 3.00e\text{-}10$), which now encompasses almost all non UV-mutants
115 analyzed (Figure 3a).

116 Recently, TCGA cutaneous melanoma patients have been classified into four molecular
117 mutation subgroups: 1- *BRAF*, associated with younger patients and with *BRAF* and *MITF*
118 amplifications; 2- *RAS*, associated with MAPK activation and AKT3 overexpression; 3- *NF1*,
119 associated with older patients and higher mutation burden; 4- The triple negative (TN), which is
120 wild-type for *BRAF*, *RAS* and *NF-1*, lacks the UV mutational signature and has higher copy

121 number and complex rearrangements⁹. Indeed, we observed that the TN molecular subgroup is
122 significantly enriched in non UV-mutant patients in both BCH and TCGA cohorts (Figures 3a-b).
123 We also observed that the *BRAF* mutant group was the most enriched in UV-mutant patients in
124 both BCH and TCGA, though reaching statistical significance only in BCH (Figures 3a-b). This
125 was in line with other studies^{15,16}, further reinforcing the reproducibility potential of our data.
126 Interestingly, *BRAF*, *NF1* and *RAS* were not significantly differentially methylated in melanoma
127 tissues in relation to UV exposure (Supplementary Data 7-8), highlighting that UV exposure
128 produces DNA methylation changes in genes that can be different from critical ones mutationally
129 altered by the same environmental exposure.

130 Jensen disease analysis of the filtered DMRs showed a significant implication of the
131 differentially methylated genes in skin disorders, such as systemic sclerosis (BCH and TCGA),
132 vitiligo (BCH and TCGA), melanoma (BCH), and skin cancer (BCH), particularly among the top
133 and false discovery rate (FDR)-adjusted ontologies (FDR < 0.05) (Supplementary Data 9-10). A
134 number of other cancers and diseases were significantly enriched as well (Supplementary Data
135 9-10). This was complemented by KEGG pathway analysis, revealing 28 and 30 significant
136 pathways ($p < 0.05$) in BCH and TCGA, respectively. Among them, a large proportion (10
137 pathways) were identical between BCH and TCGA, 8 and 6 of which remained significant after
138 adjustment for the number of CpGs per gene and FDR, respectively (Figure 3c, Supplementary
139 Data 11-14). These pathways constituted of differentially methylated genes implicated in immune
140 system regulation: hematopoietic cell lineage, allograft rejection, graft-versus-host disease,
141 intestinal immune network for IgA production, antigen processing presentation, inflammatory
142 bowel disease, and relatedly, autoimmune diseases, such as type 1 diabetes mellitus,
143 autoimmune thyroid disease, systemic lupus erythematosus and rheumatoid arthritis (Figure 3c).

144 The role of DNA methylation alterations in regulating immune system function was
145 investigated in further depth and validated using RNA sequencing data (Methods section),
146 demonstrating that immune cell composition was indeed different between UV-mutant and non

147 UV-mutant cutaneous melanoma patients (Figure 3d). Specifically, dendritic cells were
148 significantly infiltrated in the non UV-mutant than in UV-mutant cutaneous melanoma (Figure 3d,
149 $p = 0.03$). Complementary analysis using differentially expressed genes comparing non UV-
150 mutant and UV-mutant cutaneous melanoma patients ($p < 0.05$, Supplementary Data 15) also
151 showed enrichment in immune disorders and skin-related diseases, though none reached FDR
152 significance (Supplementary Data 16-17).

153

154 **DNA methylome markers of UV are prognostic of patient survival**

155 In addition to the large proportion of overlap in biological pathways between BCH and
156 TCGA described above, there was a significant overlap in DNA methylation alterations at the gene
157 and CpG levels between BCH and TCGA (Figure 4a). Out of the 458 CpGs from 169 genes
158 significantly overlapping ($p = 2.3e-109$ and $p = 3.71e-29$, respectively) between BCH and TCGA
159 cohorts (Supplementary Data 18, Figure 4a), 6 CpGs (*HOXC9*, *KCNQ1DN* and *MGMT* genes)
160 were hypermethylated and 30 CpGs (*TAPBP*, *ERICH3*, *FINL2*, *ZNF732*, *SLC6A18*, *MFSD13A*,
161 *SLFN12L* and *IFNLR1* genes) were hypomethylated in both BCH and TCGA, considering CpGs
162 with absolute effect sizes $\geq 10\%$ and with no significant enrichment in SNPs (Supplementary Fig.
163 1b-c).

164 We complemented the cohort-specific analyses with a DMR meta-analysis across the
165 BCH and TCGA datasets (Figure 4b). As the results demonstrate, there are 45,915 CpGs
166 significantly differentially methylated across the two datasets between UV-mutant and non UV-
167 mutant cutaneous melanomas (FDR < 0.05), of which a high proportion of CpGs (equal to 24,711
168 CpGs or equivalent to 53.8%) have the same direction of effect between BCH and TCGA
169 (Supplementary Data 19, Figure 4b). 121 meta-analysis CpGs (FDR < 0.05) overlapped with the
170 458 CpGs that are common between the BCH and TCGA cohort-specific analyses. As expected,
171 the meta-analysis yields a larger number of significant hits (due to higher statistical power) than
172 the cohort-specific analyses. However, the former is more prone to false positivity especially given

173 some clinicopathological and ethnic dissimilarities (Table 1) and methodological differences
174 between the two cohorts in predicting UV signature status (WGS versus WES, respectively). For
175 this reason, (1) we additionally report the more stringent Bonferroni threshold, which yielded
176 similar results as FDR (Supplementary Data 20, Figure 4b), and (2) we present the meta-analysis
177 results as a complementary method that reinforces the robustness of the findings across the
178 different cohorts and analysis approaches, while prioritizing the more conservative cohort-specific
179 analysis which yields signals that are common between BCH and TCGA and which, though less
180 profuse, are less prone to error.

181 Thus, we further investigated whether the 36 CpGs in common between BCH and TCGA
182 could be used to predict the survival of patients with cutaneous melanoma. Among them,
183 cg06230948-*TAPBP*, cg18930100-*TAPBP*, cg19495013-*FIGNL2* and cg26835312-*IFNLR1* were
184 significantly associated with survival in BCH after adjustment for multiple testing (FDR < 0.05)
185 (Supplementary Data 21). Among these four CpGs, cg18930100-*TAPBP* was also significantly
186 associated with survival in a lookup analysis in TCGA. Specifically, patients in the low methylation
187 groups at this CpG site had significantly higher melanoma-specific survival in both cohorts
188 (Supplementary Data 21 and Figure 4c). This was concordant with the observed hypomethylation
189 effects at this CpG (Figure 4d) that are associated with increased survival (Figure 2a) in UV-
190 mutant relative to non UV-mutant patients. Notably, *TAPBP* differential methylation is robustly
191 significant in both the cohort-specific and meta-analyses of the BCH and TCGA cohorts (Figure
192 4b and Supplementary Data 7,8,19 and 20).

193

194 **Validation and multi-OMICs functional roles of UV methylome markers**

195 We next investigated the functional effect of UV-related DNA methylation alterations on
196 gene expression using expression quantitative trait methylation (eQTM) analysis applied to DNA
197 methylome and transcriptome data profiled on the same samples (Figure 1). We first used a
198 targeted approach focusing on cg18930100-*TAPBP* prioritized in the previous analysis (Figure 4)

199 and found that its methylation levels were significantly correlated with *TAPBP* RNA expression
200 changes (Figure 5a). We then performed eQTM analysis on all 458 CpGs that are common
201 between TCGA and BCH (Supplementary Fig. 2a) in order to investigate whether the *TAPBP*
202 gene could be still identified agnostically among the eQTMs. Out of the 458 CpGs, 10 (*TAPBP*:
203 cg01253676, cg01654446, cg06230948, cg06375761, cg02863594, cg18930100, cg18353226;
204 and *EIF2AK4*: cg20255370, cg16127683, cg01081584) were significantly correlated with
205 expression, among which 7 CpGs were indeed located in the *TAPBP* gene, including its
206 cg18930100 (Figure 5a). All the significant correlations showed an inverse association between
207 CpG methylation and RNA expression levels of each gene, with *TAPBP* showing hypomethylation
208 while *EIF2AK4* showing hypermethylation in UV-mutant relative to non UV-mutant cutaneous
209 melanoma patients (Figure 5a). Notably, cg18930100 in *TAPBP* presented hypomethylation
210 associated with both increased *TAPBP* RNA expression (Figure 5a) and increased patient
211 survival (Figure 4c) in UV-mutant relative to non UV-mutant cutaneous melanoma patients.
212 *TAPBP* and *EIF2AK4* RNA expression levels did not significantly associate with patient survival
213 (Supplementary Fig. 2b), suggesting that their methylation levels may be stronger prognostic
214 markers than their transcript levels.

215 Next, we pooled all 36 CpGs prioritized in Supplementary Fig. 1b (being common between
216 BCH and TCGA) with the 10 CpGs prioritized in Supplementary Fig. 2a (being significant eQTMs)
217 and investigated their cancer driver potential derived from our recent multi-OMICs driver score¹⁷.
218 This was performed using data on copy number variation, point mutations, RNA expression and
219 DNA methylation profiled in cutaneous melanoma patients. We found that the top half of the CpGs
220 with the highest cancer driver potential were largely predominated by CpGs of the *TAPBP* gene
221 (Figure 5b) and that this gene ranked among the top 4 driver genes when methylation levels were
222 averaged across CpGs of a given gene (Supplementary Fig. 2c).

223 As a positive control, we used a list of genes known to play driver roles in cutaneous
224 melanoma based on the ConsensusDriver score method (i.e. with ConsensusDriver > 1.5)¹⁸,

225 which preferentially selects cancer driver genes that are frequently mutated in tumor tissues. We
226 calculated the multi-OMICs driver scores for those genes, derived by measuring the extent of their
227 OMICs alterations in UV-mutant relative to non UV-mutant melanomas (Supplementary Fig. 2d),
228 as was done for the experimental gene set (Figure 5b). We found that the multi-OMICs driver
229 scores of the latter, including *TAPBP*, were predominantly in the same range as that of the positive
230 control genes (1.24 - 2.50) (Supplementary Fig. 2d), reinforcing the cancer driver potential of the
231 the experimental gene set relative to known driver genes in melanoma.

232 Because of the biological and clinical relevance of *TAPBP* methylation, which was
233 correlated with melanoma-specific survival and RNA expression and concurred with other
234 genome-wide deregulations that led to its high multi-OMICs driver potential, we performed
235 technical validation of *TAPBP* methylation using bisulfite pyrosequencing in the BCH cohort
236 (Supplementary Data 22). Methylation by pyrosequencing validated that obtained with the
237 methylome-wide array, confirming the observed *TAPBP* hypomethylation (including similar effect
238 sizes and baseline methylation levels) in UV-mutant relative to non UV-mutant cutaneous
239 melanoma (Figure 5c).

240

241 **Cutaneous and acral melanoma cross-OMICs: UV versus pathobiology**

242 In addition to the genome- and methylome-wide analysis of UV exposure status in
243 cutaneous melanoma, we next investigated whether the transcriptome landscape, taken alone or
244 integrated with the methylome map, can better distinguish UV-mutant from non UV-mutant
245 melanomas (Figure 1). Based on PLS-DA modelling (Methods section), we observed that the
246 DNA methylome alone predicts the two groups of patients (Figure 6A – left panel) better than the
247 transcriptome alone (Figure 6a – right panel). The discriminative potential of the DNA methylome
248 between UV-mutant and non UV-mutant cutaneous melanomas was sufficiently powerful, with
249 slight or no improvement observed by the integrated methylome-transcriptome map (Figure 6b
250 and Supplementary Data 23) using LASSO coupled to DIABLO (Methods section). This

251 complemented our earlier results showing that DNA methylation levels altered in UV-mutant
252 melanomas are more prognostic to patient survival than the transcript levels of the corresponding
253 genes (Figures 4 and Supplementary Fig 2b).

254 We further investigated whether the DNA methylome could also underlie differences
255 between pathologically different melanomas, with interaction by UV mutation status, namely
256 between melanoma types predominantly associated with UV exposure (cutaneous melanoma)
257 and those not UV-associated (acral melanoma). Table 1 shows the clinical annotations of the
258 acral samples collected at BCH. In contrast to cutaneous melanomas, out of 21 acral, only a few
259 (19.0% compared to 81.5% in BCH cutaneous melanoma, $p=4.24e-07$) had the UV mutation
260 signature as expected. The majority (47.6%) of the acral melanoma patients did not exhibit
261 mutations in *BRAF*, *NRAS* or *NF1*, and a substantial portion (28.6% compared to 5.6% in BCH
262 cutaneous melanoma, $p=2.28e-05$) presented a pigmented skin phenotype.

263 Based on PLS-DA modelling in BCH, we observed that the DNA methylome of the non
264 UV-mutant cutaneous melanomas resembles more that of the pathologically different acral
265 melanomas than the pathologically related UV-mutant cutaneous melanomas (Figure 6c). This
266 was in line with the survival analysis showing that the non UV-mutant cutaneous melanoma
267 patients presented worse prognosis, more closely resembling that of acral melanoma patients
268 (known to have poorer prognosis) rather than that of UV-mutant cutaneous melanoma patients
269 (Figure 6d, $p<1.00e-04$).

270 The impact of tumor pathology on DNA methylome alterations was still observable,
271 however, as evident by 1,784 DMRs distinguishing non UV-mutant cutaneous and non UV-mutant
272 acral melanomas (Supplementary Data 24). Jensen disease ontology and KEGG pathway
273 analyses of the filtered DMRs (as described in Supplementary Fig. 2e and Supplementary Data
274 25) showed a significant implication ($p< 0.05$) of the differentially methylated genes in skin
275 disorders (Supplementary Data 26) and immunological pathways (Figure 6e, Supplementary Data

276 27-28), respectively, but we interpret these results with caution as none of them remained
277 significant after correcting for multiple testing ($FDR > 0.05$) (Supplementary Data 26-28).

278 Discussion

279 Melanoma is a type of skin cancer, which represents one of the most complex and
280 heterogeneous cancers compared to other cancer types¹⁹. Although the positive association
281 between UV exposure with melanoma development is well known, the underlying epigenetic
282 mechanisms have never been characterized yet in human melanoma tissues, as outlined by our
283 systematic literature search (Supplementary Data 1). With the advent of new powerful
284 technologies, such as WGS/WES, UV exposure status can now be predicted and analysed in
285 human tissues. The present study investigated DNA methylome-wide alterations associated with
286 UV mutation status in two cohorts of human cutaneous melanomas, with in-depth analysis of the
287 functional and clinical implications of those alterations, including effects on regulatory regions,
288 biological pathways, gene transcription, cancer driver potential, tumor classification and patient
289 survival. This was complemented by testing whether the DNA methylome could also underlie
290 differences between pathologically and molecularly different subtypes of melanomas with
291 interaction by UV mutation status, namely between BRAF, RAS, NF1 and TN molecular groups
292 and between melanoma types predominantly associated with UV exposure (cutaneous
293 melanoma) and those not UV-associated (acral melanoma). To date, there is only one study that
294 described the methylome landscape of acral melanomas²⁰, and our work additionally highlights
295 genes and biological pathways that are epigenetically deregulated in this uncommon melanoma
296 type in comparison with cutaneous melanoma analysed in the same cohort encompassing
297 patients of European and Latin-American descents.

298 The only available melanoma dataset with methylome and genome data for replication of
299 our BCH findings was from TCGA. The number of detectable signals was higher in the BCH
300 relative to the TCGA cohort, and this is probably not due to statistical power differences as both
301 datasets had similar sample sizes. This could be rather due in the BCH dataset to (1) the better
302 quality of samples and/or their processing using our in-house optimized automated workflow to
303 generate DNA methylome data, coupled to a priori designed sample distribution on the array that

304 minimizes confounding with batch effects based on statistical semi-randomization, and (2) more
305 accurate technology, using WGS rather than WES, to assess UV exposure. Even though there
306 were some clinicopathological and ethnic dissimilarities (Table 1) and methodological differences
307 between the two cohorts in predicting UV signature status (WGS *versus* WES, respectively), we
308 observed consistent findings in both at the CpG, gene and biological pathway levels. Moreover,
309 UV-related DNA methylation alterations showed similar distributions between BCH and TCGA in
310 hypo- and hyper-methylated regions as well as similar enrichments in regulatory and CpG density
311 regions, in skin disorders and in immunological pathways. Among the CpGs and genes
312 differentially methylated in both BCH and TCGA, methylation levels of *TAPBP* (encompassing
313 several differentially methylated CpGs) were significantly associated with RNA expression of this
314 gene, concurred with other genome-wide deregulations to yield a high multi-OMICs driver
315 potential and were significantly correlated with melanoma-specific survival. The array-based
316 methylation results of *TAPBP* were independently validated by bisulfite pyrosequencing, further
317 reinforcing the robustness of the findings and providing promising opportunities for clinical
318 application *via* pyrosequencing as a cost-effective technique.

319 *TAPBP* is a member of the immunoglobulin superfamily, which mediates the interaction
320 between newly assembled major histocompatibility complex class 1 (MHC-I) and the transporter
321 associated with antigen processing²¹. Downregulation of *TAPBP* (tapasin) protein expression has
322 been observed in multiple cancers as an immune escape mechanism of human tumors, which is
323 restored after cytokine administration, indicating that deficient *TAPBP* expression might be due
324 to dysregulation than to structural alterations²². Our findings show that *TAPBP* transcription is
325 significantly inversely associated with its DNA methylation levels, and the latter are altered in
326 relation to UV exposure rather than to melanoma pathological identity since this gene was not
327 found to be differentially methylated in non UV-mutant cutaneous *versus* acral melanomas
328 (Supplementary Data 25).

329 MHC-I complex expression on tumor cells has been described as an excellent surrogate
330 marker of the overall tumor immunogenicity level as well as a predictor of response to immune
331 checkpoint blockade therapy²³. Moreover, MHC-I downregulation was identified as a common
332 mechanism of resistance to PD-I inhibitor in melanoma clinical samples²⁴. Restoring TAPBP
333 expression can enhance MHC-I (HLA-B and -C) expression, as demonstrated *in vitro*, highlighting
334 the possibility that patients with defects in MHC-I antigen-processing machinery may benefit from
335 combining immunotherapeutic strategies with demethylating agents (such as those that could
336 restore TAPBP expression)²⁵. In complement with *TAPBP*, several HLA genes were also
337 differentially methylated in UV-mutant *versus* non UV-mutant cutaneous melanoma in both BCH
338 and TCGA, and these genes were centrally involved in the multiple immunological pathways
339 identified (Figure 3c). Taken together, *TAPBP* and MHC-I machinery genes, dysregulated by DNA
340 methylation mechanisms as observed in our study, represent promising targets for epigenetic
341 therapy and for predicting clinical response to immunotherapy.

342 *TAPBP* methylation significantly predicted patient prognosis in both BCH and TCGA. Even
343 though the sample size of expression data was the same as that of methylation data, the
344 association between TAPBP expression and survival was not significant. This suggests that the
345 difference is not merely due to statistical power but could indeed reflect biological basis. DNA
346 methylation does not act solely through affecting gene transcription but is known to also associate
347 with chromosomal instability, the induction of splice variants, alterations in enhancer regions,
348 changes in microRNA binding regions and expression control regions, and mutations²⁶⁻²⁸. Hence,
349 DNA methylation may function as a prognostic marker *per se* or through these various non
350 expression-related mechanisms. Our observation is in line with a multitude of studies highlighting
351 the high sensitivity of the epigenome to exposure and risk factors^{12,29}.

352 The relation between *TAPBP* methylation and survival may not be necessarily causal. Our
353 results, however, pinpoint to an increased likelihood of causality because (1) they were
354 reproduced in two independent populations, including different ethnicities, which offer a natural

355 means of effect randomization (hence, minimizing the influence of confounders), (2) they showed
356 a dose-response (*TAPBP* hypomethylation was associated with increased survival relative to
357 hypermethylation), and (3) they yielded a cancer driver potential for *TAPBP* that was comparable
358 to that of known cancer driver genes. Still, more datasets will be needed to better reinforce the
359 causality of the associations, for example, by using in larger sample sizes germline data as
360 proxies for *TAPBP* methylation through Mendelian Randomization.

361 In addition to the findings focused on *TAPBP*, we reported that the UV mutational
362 signature is associated with a high load (thousands) of epigenetic alterations affecting the
363 methylome landscape of cutaneous melanoma. This highlights that, even though the UV-mutant
364 and non UV-mutant cutaneous melanomas are supposed to share the same pathological/cellular
365 origin, they may need to be classified separately, at least based on their underlying epigenomic
366 landscape, which has the potential to capture markers of both exposures and cell identity.
367 Moreover, the non UV-mutant cutaneous melanoma, by resembling in its epigenome the acral
368 melanoma, may have a poorer prognosis and require a different therapeutic approach than the
369 UV-exposed cutaneous melanoma. This is in line with our data showing that patient survival is
370 worse for the non UV-mutant cutaneous and acral melanomas relative to the UV-mutant
371 cutaneous melanomas. Our findings also corroborate those of another study showing that
372 cutaneous melanoma patients harboring the UV mutation signature had higher disease-free and
373 overall survival¹¹. The consistency between findings is notable especially that our dataset included
374 a different ethnic group and a more accurate methodology (WGS rather than WES) to predict the
375 UV signature.

376 To date there is only one recent study that investigated the genetic changes related to UV
377 in clinical melanoma samples and found 10 genes commonly mutated in UV-mutant relative to
378 non UV-mutant cutaneous melanoma¹¹. Among them, *PKHD1L1*, *LRP1B*, *ADGRV1* and *DNAH10*
379 were hypomethylated in UV-mutant compared with non UV-mutant cutaneous melanoma patients
380 in BCH (Supplementary Fig. 3a). Moreover, methylation of 6 CpGs of *LRP1B* were significantly

381 associated with melanoma-specific survival (FDR < 0.05) (Supplementary Data 29); the most
382 significant of those CpGs was cg02322989, the hypomethylation of which was associated with
383 higher melanoma-specific survival (Supplementary Fig. 3b). The TCGA cohort did not corroborate
384 the DMRs of these genes.

385 Consensus driver³⁰ and secondary driver genes have been recently described in
386 cutaneous melanoma³¹, among which several were differentially methylated in UV-mutant *versus*
387 non UV-mutant cutaneous melanomas patients in our analysis (*COL5A1*, *DACH1*, *MECOM*,
388 *PTEN*, *TP53*, *BRD9*, *BCL7*, *SPRED1*, *SIGLEC12* and *SIGLEC10*) (Supplementary Data 2-6).
389 These driver genes were derived mostly based on genomic data. We identified driver genes in
390 melanoma and validated others already described, based on our multi-OMICs driver score
391 encompassing genomics, transcriptomics and DNA methylome data. Our results suggest that
392 genes differentially methylated in response to UV may play driver mechanisms in melanoma
393 development.

394 In this work, we applied a battery of powerful technology, encompassing WGS, WES, RNA
395 sequencing and DNA methylome-wide profiling, coupled to state-of-the-art bioinformatics tools
396 onto a unique series of cutaneous and acral melanoma samples. Specifically, we leveraged
397 publicly available data and complemented that with the generation of new datasets, with larger
398 sample sizes, higher genomic coverage, more detailed phenotypic assessment, high-quality
399 frozen tissue samples, and the inclusion of melanomas other than cutaneous and of ethnicities
400 besides European-descent. In fact, less than 5% of genetic studies worldwide include participants
401 with multiple ancestry³², specifically in acral melanoma research³³, and our work helps address
402 this timely advocated need^{32,33} by contributing to genomics and epigenomics data from
403 populations of non-European descent. By investigating epigenetic markers of UV exposure in
404 human melanoma tissues from two distinct populations and overlaying the DNA methylome
405 landscape onto the transcriptome and genome maps of UV-mutant cutaneous relative to non UV-
406 mutant cutaneous and acral melanomas, this work contributes to (1) uncovering potentially

407 powerful exposure and cancer epigenetic biomarkers that can be exploited in risk stratification;
408 (2) enhancing tumor classification within and across melanoma types; (3) revealing molecular
409 drivers in melanomagenesis that could be at the origins of this cancer, hence, suitable for targeted
410 therapy; and (4) diminishing population disparities and knowledge inequalities in melanoma
411 pathobiology. The translational impact of the work covers common and less frequent melanomas
412 and offers a roadmap guiding similar gene-environment investigations of other melanoma types.

413

414 **Methods**

415 Patient eligibility, biospecimen and clinical data

416 The study was conducted according to the Brazilian national and institutional ethical
417 policies, and it was previously approved by the Barretos Cancer Hospital Ethics Committee
418 (716/2013). No compensation was provided to the participants in this study and informed consent
419 was obtained by all participants included in BCH cohort. Patients were recruited at BCH in the
420 context of the ICGC-Brazil project, which encompassed 100 melanoma patients prior to any
421 systemic treatment and from whom paired tumor/blood tissues were profiled by WGS³⁴ and tumor
422 tissues by 450K DNA methylation array. We selected two subsets of patients from ICGC-Brazil
423 (BCH cohort): first, Discovery cohort 1, encompassing 54 cutaneous melanomas patients
424 harboring or not the UV mutation signature; second, Discovery cohort 3, constituting of 17 acral
425 melanomas that are non UV-mutant (Figure 1), after having excluded the 4 acral samples that
426 were UV-mutant. All BCH samples were fresh frozen. Clinicopathological data were collected
427 under ICGC guidelines. During the admission process at BCH, all patients self-report their skin
428 type and ethnicity, and this information was extracted from medical records given the
429 retrospective nature of the study. In addition, several studies were conducted on this patient
430 population to determine their genetic-based ethnicity and correlate their ancestry with clinical
431 characteristics. These studies observed considerable admixture in the genetic composition³⁵⁻³⁸.

432 The second cohort comprised 58 cutaneous melanoma samples from TCGA-
433 SKCM for which information about UV signature was available (Figure 1) based on WES. We
434 excluded formalin fixed paraffin embedded samples and selected only fresh frozen samples for
435 best quality of data and to eliminate sample processing bias in our comparisons with BCH
436 samples. Clinicopathological data were downloaded from the TCGA-SKCM published study⁹.

437

438 DNA isolation

439 DNA from fresh frozen BCH-cohort samples were isolated using the DNA Mini
440 Qiasymphony kit (Qiagen catalog no 937236) following BCH Biobank procedures and the
441 manufacturer's instructions³⁹. Briefly, approximately 25 mg tissue in 180 μ L ATL Buffer was
442 homogenized (Precellys, Bertin-instruments) at 6,500 1x10/10 seconds for three times. After
443 samples were centrifuged for 1 minute at 2,867 xg, supernatants were transferred for another
444 tube, 25 μ L of Proteinase K were added per sample, and samples were incubated at 56°C, 134
445 xg for 3 hours. Then 4 μ L RNase were added per sample and DNA was isolated using
446 QIASymphony (Qiagen catalog no 9001297).

447

448 Whole genome and exome sequencing and prediction of UV mutational signatures

449 The WGS library construction and sequencing of BCH samples were performed at
450 Mendelics (São Paulo, SP, Brazil). A total amount of one ug of each matched normal and tumor
451 DNA was submitted to sonication fragmentation and further library preparation by Illumina TruSeq
452 DNA PCR-Free Library Preparation kit (Illumina catalog no 20015963) using the 350 bp protocol.
453 Libraries were quantified by Qubit Fluorometer (Thermofisher catalog no Q33238) and qualified
454 by 2100 Bioanalyzer (Agilent catalog no G2939BA). The sequencing was carried out using
455 Illumina HiSeq 2500 by paired-end strategy at a minimum of 30X coverage. WES data of TCGA
456 samples was available from GDC Legacy Portal⁹. Molecular subgroups were defined by
457 investigating somatic single-nucleotide mutations in *BRAF* hotspot, *RAS* hotspot

458 and *NF1* throughout Mutect⁴⁰ algorithm and further annotated using Annovar⁴¹. The TN molecular
459 subgroup denoted melanoma patients who did not harbour mutations in any of the three genes³⁴.

460 The UV mutational signature identification was performed using the SomaticSignatures
461 Bioconductor package⁴². We used the Non-negative Matrix Factorization (NMF) algorithm⁴³ to
462 determine the consensus signatures among the 71 patients. At the moment of the analyses, we
463 used the 21 signatures¹⁰ that were available and identified a consensus signature with more than
464 0.8 cosine similarity. For both BCH and TCGA cohorts, we classified samples as harboring an
465 UV mutation signature (Cosmic Signature 7) based on the recommended criteria in which C>T
466 transitions at dipyrimidine sites accounted for more than 60% or CC>TT mutations more than 5%
467 of the total mutation burden⁹.

468

469 Bisulfite conversion

470 The isolated DNA (500 ng) from BCH-cohort was bisulfite-modified using the EZ DNA
471 Methylation Kit (Zymo Research catalog no #ZD5004) following the manufacturer's instructions
472 for Illumina Infinium 450K beadchip assay. Modified DNA was stored at -20°C when short intervals
473 were required between bisulfite conversion and further processing, and at -80°C for long-term
474 storage.

475

476 450K DNA methylome-wide array and analysis

477 The 450K data of BCH were generated in-house, and those of TCGA were downloaded
478 from the GDC Legacy Portal⁹. For BCH, bisulfite converted DNA samples were profiled using
479 450K (Illumina catalog no WG-314-1003) and a well-established workflow optimized at the IARC
480 Epigenomics and Mechanisms Branch for high-throughput analyses through an automated
481 robotic system (Freedom EVO 150 by Teca) that can process the chips with minimal human error.
482 Chips are scanned using Illumina iScan to produce two-color raw data files (.idat format). Sample
483 allocation to the arrays was based on a semi-randomization design that ensures minimum

484 confounding by technical variation and minimizes the masking of biological covariates of interest
485 by batch effects.

486 For the bioinformatics pre-processing, IDAT files from both cohorts were imported and
487 processed using R software. Quality-control graphs and bimodal distributions for each dataset
488 are shown in Supplementary Fig. 4-5. We excluded cross-reactive probes and XY chromosomes,
489 leaving a total of 459,761, 459,770 and 459,768 probes for the analysis in BCH-Cutaneous, BCH-
490 Acral and TCGA cohort, respectively. The data were further normalized using the FunNorm
491 function of the Bioconductor Minfi package⁴⁴ (Supplementary Fig. 4), that was shown to perform
492 equally good or outperform existing normalization methods⁴⁵. Inferred beta values were used to
493 predict sex as a quality-control step using the Minfi function getSex. All samples were correctly
494 predicted. The DNA methylation level β -values were logit transformed to M-values to map the
495 range (0,1) to (-inf,+inf) as it is more suitable for running regressions. Surrogate variable analysis
496 (SVA) was performed on the methylome data to correct for potential batch effects, to adjust for
497 differences in cell type composition as a reference-free method⁴⁶, and to adjust for latent
498 variables, a choice validated by the findings of our benchmarking⁴⁷. SVA also increases statistical
499 power by removing (unwanted) variability through aggregating information at the data level and
500 constraining the data's variability to the phenotype of interest⁴⁸.

501 For the statistical analysis, we used robust linear regression (robust to outliers) to test four
502 statistical models in the discovery cohort 1 (BCH), including one crude and three adjusted models,
503 comparing the DNA methylome of UV-mutant *versus* non UV-mutant cutaneous melanoma
504 patients (Supplementary Fig, 5-6): 1- Crude Model (Supplementary Data 2); 2- Adjusted Model 1
505 adjusted for sex (Supplementary Data 3); 3- Adjusted Model 2, adjusted for sex + age at diagnosis
506 (Supplementary Data 4); and 4- Adjusted Model 3, adjusted for sex + age at diagnosis + tumor
507 type (primary or metastasis) (Supplementary Data 5). Supplementary Fig. 5 shows quantile-
508 quantile (Q-Q) plots of $-\log_{10}P$ values, which deviate from their expected values under the null
509 hypothesis across all models. Although the adjusted models yielded a larger number of significant

510 findings relative to the crude model (Supplementary Fig. 6), we preferred to take a conservative
511 approach and focus our analysis on the crude model, especially that it showed the least genomic
512 inflation and risk of false positives, with a lambda of 1.20 (i.e. approaching to 1.0 being the no
513 inflation limit) (Supplementary Fig. 5). Moreover, the predominant proportion of significant
514 findings in the crude model was actually common with any of the adjusted models (Supplementary
515 Fig. 6b). We also compared for each model, two approaches of methylome-wide analysis: the
516 Differentially Methylated CpG Probes (DMPs), analysing individual CpGs using the Bioconductor
517 limma package⁴⁹, and the DMRs, analysing regions of genomically proximal CpGs using the
518 Bioconductor DMRcate⁵⁰ package with the default proximity-based criteria (± 1000 base pairs).
519 At least 90% of DMP-based genes overlapped with those derived from DMRs across all models
520 (Supplementary Fig. 6a). For this reason and because DMR analysis represents a dimension
521 reduction approach with higher statistical power than DMP analysis, we focused downstream
522 analyses in BCH and TCGA data onto the DMR approach applied to the crude model. This
523 pipeline was equally applied to the DNA methylome comparison between non UV-mutant acral
524 and non UV-mutant cutaneous melanomas. Statistically significant DMPs and DMRs were defined
525 as those with FDR-adjusted P value < 0.05 .

526 We complemented the cohort-specific analysis by a meta-analysis across the BCH and
527 TCGA cohorts comparing UV-mutant *versus* non UV-mutant cutaneous melanoma patients. We
528 used the Metal tool⁵¹ and the Dmrff package in R to perform DMR fixed effects inverse variance
529 weighted meta-analysis⁵², using the crude model as prioritized in the cohort-specific analysis. The
530 meta-analysis lambda value was 1.16, showing low inflation. Statistically significant DMRs were
531 defined as those with FDR-adjusted P value < 0.05 . Due to the larger number of hits expected
532 with the increased statistical power afforded by the meta-analyses, we also reported the more
533 stringent Bonferroni-adjusted p values, especially considering the higher likelihood of false
534 positivity due to clinicopathological, ethnic and methodological differences between meta-
535 analysed BCH and TCGA.

536 In addition to generating DMPs and DMRs, methylation data from BCH and TCGA
537 samples were further investigated using Partial Least Squares Discriminant Analysis (PLS-DA)⁵³.
538 This approach performs classification of samples using partial least squares regression of the
539 categorical outcome Y (cancer subtype) on the predictor variables (DNA methylation). PLS-DA is
540 a clustering technique that allows the quantification of the discrimination relevance of a given
541 variable (CpG) and to predict the phenotype of new samples (independent of DMPs or DMRs).
542 This method is especially suited to deal with a much larger number of variables than samples, as
543 in next-generation microarray and sequencing data, and we aided this method further by a filtering
544 step using median absolute deviation (MAD)⁵⁴. We selected the 100 most variable CpGs and
545 applied PLS-DA on the methylation matrix on this subset of sites to assess the discriminative
546 potential of the DNA methylome between UV-mutant and non UV-mutant cutaneous melanomas
547 (as well as acral melanomas in the case of BCH samples).

548

549 Pyrosequencing methylation analysis

550 For the quantitative measurement of DNA methylation levels in individual CpG sites of the
551 *TAPBP* (7 CpGs) gene (Supplementary Data 22), we pyrosequenced the bisulfite converted DNA
552 using the PyroMark Kit (Qiagen catalog no 978703) as per the manufacturer's instruction. Briefly,
553 DNA was immobilized onto streptavidin-coated beads in binding buffer for 10 min. The biotin-
554 labeled PCR template was isolated and denatured using the pyrosequencing vacuum prep tool
555 and incubated with 0.4 μ M sequencing primer in annealing buffer (20 mM Tris-acetate, 2 mM
556 MgAc₂; pH 7.6). The reaction was incubated at 80°C for 2 min and cooled down to room
557 temperature for 20 min to allow sequencing primer annealing. The methylation levels at the target
558 CpGs were evaluated by converting the resulting pyrograms to numerical values for peak heights
559 and expressed as the average of all patients for a given CpG site analyzed.

560

561 RNA expression data and analysis

562 Transcriptome data, measured by RNA sequencing (RNAseq), were downloaded from
563 TCGA-SKCM project⁹ and normalized with DESeq package⁵⁵. As with the DNA methylation data,
564 the normalized RNAseq data was first filtered by MAD for the 100 most variable transcripts and
565 then analysed by PLS-DA to assess the discriminative potential of the transcriptome between UV-
566 mutant and non UV-mutant cutaneous melanomas. We used quanTiseq package⁵⁶ to estimate
567 the fractions of ten immune cell types using the RNAseq from TCGA-SKCM project⁹, comparing
568 UV and non UV-mutant melanoma patients. Then Mann-Whitney U Test was performed to
569 compare the two conditions as this non-parametric test is robust to outliers, which were detected
570 in some data points of the various cell types.

571
572 Gene ontology and pathway analysis

573 Gene ontology and pathway analysis were performed using the Jensen Disease ontology
574 and KEGG pathway databases available on Enrich-r website^{57,58}
575 (<https://maayanlab.cloud/Enrichr>). Given that genes with larger numbers of probes are more likely
576 to have significantly differentially methylated CpGs, potentially biasing gene set analysis, we
577 implemented the *gometh* function of the missMethyl package⁵⁹ in R to adjust for the number of
578 CpGs per gene, which ranges on the 450K array from 1 to 1,299 CpGs.

579
580 Cross-OMICs and integrative analysis

581 Regarding eQTM, we applied Pearson correlation between RNA expression and DNA
582 methylation data of the 169 genes that are common between BCH and TCGA DMRs, while limiting
583 the analysis of a given gene to its constituent CpGs.

584 For the integrated methylome-transcriptome analysis, we filtered each of the 450K and
585 RNAseq datasets by MAD and applied PLS-DA independently to each OMICs, as described in
586 previous sections. Next, we applied sparse PLS-DA⁶⁰ that uses LASSO⁶¹ penalization technique
587 to select the 25 most informative CpGs and transcript probes in each dataset (Supplementary

588 Data 23). We then applied an integrative analysis on the subsets of methylation and
589 transcriptomic data, together with UV exposure outcome. We used the DIABLO method to gain a
590 better understanding of the interplay between the different levels of data that are measured⁶². All
591 these analyses were done using mixOmics R package⁶³.

592 For the prediction of multi-OMICs driver score, genome, transcriptome and DNA
593 methylome data were downloaded from TCGA-SKCM (473 cases)⁹. Then, we calculated for each
594 gene: [CNV: Copy Number Variation], being the number of tumors affected by a deep insertion (\geq
595 +2) or a deep deletion (\leq -2), and this number was divided by the maximum CNV value obtained
596 across the analysed genes in order to generate the CNV score; [MUT: Mutation], being the
597 number of tumors affected by at least one single nucleotide alteration, and this number was
598 divided by the maximum MUT value obtained across the analysed genes in order to generate the
599 MUT score; [EXP: Expression], being the number of UV-mutant cases presenting variations in
600 RNA expression ($|\log_{2}FC| > 2$) relative to non UV-mutant patients, and this number was divided by
601 the maximum EXP value obtained across the analysed genes in order to generate the EXP score;
602 and [METH: Methylation], being the number of UV-mutant cases presenting variations in
603 methylation ($|\Delta\beta| > 0.1$) relative to non UV-mutant patients, and this number was divided
604 by the maximum METH value obtained across the analysed genes in order to generate the METH
605 score. The driver score for each gene was then calculated as the sum of these four proportions,
606 representing a derivation of our recently reported cancer driver score¹⁷ by additionally including
607 DNA methylation data on top of genomic and transcriptomic data.

608

609 Power estimates

610 The OMIC with the largest dimension (*i.e.* involving an agnostic approach with a multitude
611 of statistical tests) would require the largest number of samples analysed to maintain a high
612 statistical power. In this work, it would be the DNA methylome (~450,000 tests) followed by the
613 transcriptome (~20,000 tests). Although WGS has a larger dimension than either, it is not being

614 used agnostically in this work, but rather to screen for specific mutational signatures or mutated
615 genes known to be genetically altered in melanoma. Accordingly, statistical power is estimated
616 based on the methylome as such: the overall mean standard deviation (SD) of methylation probes
617 in the BCH or TCGA data is 0.11 (for methylation values ranging 0-1). Given an effect size $\geq 10\%$
618 methylation difference (a threshold used in our prioritization filters as reported in Supplementary
619 Fig. 1a-b and Supplementary Fig 2a) and based on an alpha of 0.05, we will have $>80\%$ power
620 with at least 20 exposed cases and 20 controls. Our sample size is larger and encompasses 21
621 UV-mutant cutaneous and 91 non UV-mutant cutaneous melanomas from BCH and TCGA. In
622 addition to single OMIC analysis, we performed integrative OMICs analysis, which can depict
623 small effects shared between OMICs and not detected in the individual analyses and, hence,
624 could be performed on smaller sample sizes than single-OMIC analysis. A recent study also
625 proposes a joint power method for all OMICs being integrated⁶⁴; however, we preferred to
626 estimate the power based on the OMICs with the largest dimension as a more conservative
627 approach. Statistical power was further enhanced by implementing dimension reduction and SVA
628 approaches (as described in the 450K analysis), and the false positive likelihood was reduced by
629 monitoring and correcting for potential inflation, by adjusting for multiple-testing, and by replication
630 of findings in two independent cohorts as well as by two different techniques (array- and
631 pyrosequencing-based).

632

633 Other statistical analyses

634 Enrichment analyses was done using Chi-Square test or, when sample sizes were small,
635 Fisher's exact test as proposed by R. For Kaplan-Meier melanoma-specific survival analyses,
636 methylation data were dichotomized using the mean methylation level as cut-off, and log-rank
637 testing was used to evaluate differences between curves⁶⁵. The various plots in the manuscript
638 were generated using ggplot2 package⁶⁶, except for the heatmaps, which were generated using

639 Heatmap plus package. All analyses were performed on R. P Values ≤ 0.05 were considered
640 statistically significant. Adjustment for multiple testing was based on FDR < 0.05 .

641

642 Systematic literature search

643 We performed a systematic literature search on PubMed to select papers published until
644 May 2021 that analyzed DNA methylome-wide data in clinical melanoma samples. To this end,
645 we used the following syntax: ((melanoma) OR (melanomas)) AND ((Global DNA methylation)
646 OR (methylome) OR (methylome-wide) OR (DNA methylation)). In total, we found 867 studies of
647 which 20 (Supplementary Data 1) were included in our analysis since they covered methylome-
648 wide profiling rather than targeted DNA methylation assays, and they were also conducted on
649 clinical samples rather than cell lines or animal models.

650

651 **Data Availability**

652 The 450K data generated in this study have been deposited in the GEO database under
653 accession code GSE202750 [<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE202750>].
654 The WGS data are available in the ICGC database [<https://dcc.icgc.org/projects/SKCA-BR>]. The
655 450K, RNAseq and WES data on melanoma samples from TCGA were downloaded from the
656 GDC Legacy Portal [<https://portal.gdc.cancer.gov/legacy-archive/search/f>] and cBioPortal
657 [<https://www.cbioportal.org/datasets>].

658

659 **Code Availability**

660 Bioinformatics pipelines used in this study are available in
661 [<https://zenodo.org/record/6530343#.Ynuzki-tFTY>]⁶⁷ under the DOI number:
662 10.5281/zenodo.6530343.

663 **References**

- 664
- 665
- 666 1. Uong, A. & Zon, L.I. Melanocytes in development and cancer. *J Cell Physiol* **222**, 38-41
667 (2010).
- 668 2. Tsao, H., Chin, L., Garraway, L.A. & Fisher, D.E. Melanoma: from mutations to
669 medicine. *Genes Dev* **26**, 1131-55 (2012).
- 670 3. Sung, H. *et al.* Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and
671 Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* **71**, 209-249
672 (2021).
- 673 4. Guy, G.P., Jr. *et al.* Vital signs: melanoma incidence and mortality trends and projections
674 - United States, 1982-2030. *MMWR Morb Mortal Wkly Rep* **64**, 591-6 (2015).
- 675 5. Boniol, M., Autier, P., Boyle, P. & Gandini, S. Cutaneous melanoma attributable to
676 sunbed use: systematic review and meta-analysis. *BMJ* **345**, e4757 (2012).
- 677 6. Clark, W.H., Jr., From, L., Bernardino, E.A. & Mihm, M.C. The histogenesis and
678 biologic behavior of primary human malignant melanomas of the skin. *Cancer Res* **29**,
679 705-27 (1969).
- 680 7. Bernardes, S.S. *et al.* More than just acral melanoma: the controversies of defining the
681 disease. *J Pathol Clin Res* (2021).
- 682 8. Bradford, P.T., Goldstein, A.M., McMaster, M.L. & Tucker, M.A. Acral lentiginous
683 melanoma: incidence and survival patterns in the United States, 1986-2005. *Arch*
684 *Dermatol* **145**, 427-34 (2009).
- 685 9. Cancer Genome Atlas, N. Genomic Classification of Cutaneous Melanoma. *Cell* **161**,
686 1681-96 (2015).
- 687 10. Alexandrov, L.B. *et al.* Signatures of mutational processes in human cancer. *Nature* **500**,
688 415-21 (2013).
- 689 11. Trucco, L.D. *et al.* Ultraviolet radiation-induced DNA damage is prognostic for outcome
690 in melanoma. *Nat Med* **25**, 221-224 (2019).
- 691 12. Herceg, Z. *et al.* Roadmap for investigating epigenome deregulation and environmental
692 origins of cancer. *Int J Cancer* **142**, 874-882 (2018).
- 693 13. Ikehata, H. & Ono, T. Significance of CpG methylation for solar UV-induced
694 mutagenesis and carcinogenesis in skin. *Photochem Photobiol* **83**, 196-204 (2007).
- 695 14. Elder, D.E., Bastian, B.C., Cree, I.A., Massi, D. & Scolyer, R.A. The 2018 World Health
696 Organization Classification of Cutaneous, Mucosal, and Uveal Melanoma: Detailed
697 Analysis of 9 Distinct Subtypes Defined by Their Evolutionary Pathway. *Arch Pathol*
698 *Lab Med* **144**, 500-522 (2020).
- 699 15. Kim, S.Y. *et al.* Metaanalysis of BRAF mutations and clinicopathologic characteristics in
700 primary melanoma. *J Am Acad Dermatol* **72**, 1036-46.e2 (2015).
- 701 16. Lee, J.H., Choi, J.W. & Kim, Y.S. Frequencies of BRAF and NRAS mutations are
702 different in histological types and sites of origin of cutaneous melanoma: a meta-analysis.
703 *Br J Dermatol* **164**, 776-84 (2011).
- 704 17. Halaburkova, A. *et al.* Pan-cancer multi-omics analysis and orthogonal experimental
705 assessment of epigenetic driver genes. *Genome Res* **30**, 1517-1532 (2020).
- 706 18. Bertrand, D. *et al.* ConsensusDriver Improves upon Individual Algorithms for Predicting
707 Driver Alterations in Different Cancer Types and Individual Patients. *Cancer Res* **78**,
708 290-301 (2018).

- 709 19. Andor, N. *et al.* Pan-cancer analysis of the extent and consequences of intratumor
710 heterogeneity. *Nat Med* **22**, 105-13 (2016).
- 711 20. Pradhan, D. *et al.* Aberrant DNA Methylation Predicts Melanoma-Specific Survival in
712 Patients with Acral Melanoma. *Cancers (Basel)* **11**(2019).
- 713 21. Ortmann, B. *et al.* A critical role for tapasin in the assembly and function of multimeric
714 MHC class I-TAP complexes. *Science* **277**, 1306-9 (1997).
- 715 22. Seliger, B. *et al.* Downregulation of the constitutive tapasin expression in human tumor
716 cells of distinct origin and its transcriptional upregulation by cytokines. *Tissue Antigens*
717 **57**, 39-45 (2001).
- 718 23. Lechner, M.G. *et al.* Immunogenicity of murine solid tumor models as a defining feature
719 of in vivo behavior and response to immunotherapy. *J Immunother* **36**, 477-89 (2013).
- 720 24. Lee, J.H. *et al.* Transcriptional downregulation of MHC class I and melanoma de-
721 differentiation in resistance to PD-1 inhibition. *Nat Commun* **11**, 1897 (2020).
- 722 25. Chang, C.C. *et al.* Multiple structural and epigenetic defects in the human leukocyte
723 antigen class I antigen presentation pathway in a recurrent metastatic melanoma
724 following immunotherapy. *J Biol Chem* **290**, 26562-75 (2015).
- 725 26. Narayanan, S.P., Singh, S. & Shukla, S. A saga of cancer epigenetics: linking epigenetics
726 to alternative splicing. *Biochem J* **474**, 885-896 (2017).
- 727 27. Cho, J.W. *et al.* The importance of enhancer methylation for epigenetic regulation of
728 tumorigenesis in squamous lung cancer. *Exp Mol Med* **54**, 12-22 (2022).
- 729 28. Anwar, S.L. & Lehmann, U. DNA methylation, microRNAs, and their crosstalk as
730 potential biomarkers in hepatocellular carcinoma. *World J Gastroenterol* **20**, 7894-913
731 (2014).
- 732 29. Bowers, E.C. & McCullough, S.D. Linking the Epigenome with Exposure Effects and
733 Susceptibility: The Epigenetic Seed and Soil Model. *Toxicol Sci* **155**, 302-314 (2017).
- 734 30. Bailey, M.H. *et al.* Comprehensive Characterization of Cancer Driver Genes and
735 Mutations. *Cell* **173**, 371-385 e18 (2018).
- 736 31. Conway, J.R. *et al.* Integrated molecular drivers coordinate biological and clinical states
737 in melanoma. *Nat Genet* **52**, 1373-1383 (2020).
- 738 32. Fatumo, S. *et al.* A roadmap to increase diversity in genomic studies. *Nature Medicine*
739 **28**, 243-250 (2022).
- 740 33. Alicea, G.M. & Rebecca, V.W. Un-Fair Skin: racial disparities in acral melanoma
741 research. *Nature Reviews Cancer* **22**, 127-128 (2022).
- 742 34. Vazquez, V.d.L. *et al.* Brazilian melanoma genome project: mutational landscape based
743 on whole-genome sequencing. in *Cancer Research* Vol. 77 (2017).
- 744 35. Duraes, R.O. *et al.* Role of Genetic Ancestry in 1,002 Brazilian Colorectal Cancer
745 Patients From Barretos Cancer Hospital. *Front Oncol* **10**, 145 (2020).
- 746 36. Leal, L.F. *et al.* Mutational profile of Brazilian lung adenocarcinoma unveils association
747 of EGFR mutations with high Asian ancestry and independent prognostic role of KRAS
748 mutations. *Sci Rep* **9**, 3209 (2019).
- 749 37. Fernandes, G.C. *et al.* Prevalence of BRCA1/BRCA2 mutations in a Brazilian population
750 sample at-risk for hereditary breast cancer and characterization of its genetic ancestry.
751 *Oncotarget* **7**, 80465-80481 (2016).
- 752 38. Berardinelli, G.N. *et al.* Association of microsatellite instability (MSI) status with the 5-
753 year outcome and genetic ancestry in a large Brazilian cohort of colorectal cancer. *Eur J*
754 *Hum Genet* (2022).

- 755 39. Neuber, A.C. *et al.* The biobank of barretos cancer hospital: 14 years of experience in
756 cancer research. *Cell Tissue Bank* (2021).
- 757 40. Lawrence, M.S. *et al.* Mutational heterogeneity in cancer and the search for new cancer-
758 associated genes. *Nature* **499**, 214-218 (2013).
- 759 41. Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic
760 variants from high-throughput sequencing data. *Nucleic Acids Res* **38**, e164 (2010).
- 761 42. Gehring, J.S., Fischer, B., Lawrence, M. & Huber, W. SomaticSignatures: inferring
762 mutational signatures from single-nucleotide variants. *Bioinformatics* **31**, 3673-5 (2015).
- 763 43. Lee, D.D. & Seung, H.S. Learning the parts of objects by non-negative matrix
764 factorization. *Nature* **401**, 788-91 (1999).
- 765 44. Aryee, M.J. *et al.* Minfi: a flexible and comprehensive Bioconductor package for the
766 analysis of Infinium DNA methylation microarrays. *Bioinformatics* **30**, 1363-9 (2014).
- 767 45. Fortin, J.P. *et al.* Functional normalization of 450k methylation array data improves
768 replication in large cancer studies. *Genome Biol* **15**, 503 (2014).
- 769 46. Kaushal, A. *et al.* Comparison of different cell type correction methods for genome-scale
770 epigenetics studies. *BMC Bioinformatics* **18**, 216 (2017).
- 771 47. Perrier, F. *et al.* Identifying and correcting epigenetics measurements for systematic
772 sources of variation. *Clin Epigenetics* **10**, 38 (2018).
- 773 48. Lin, X., Barton, S. & Holbrook, J.D. How to make DNA methylome wide association
774 studies more powerful. *Epigenomics* **8**, 1117-29 (2016).
- 775 49. Ritchie, M.E. *et al.* limma powers differential expression analyses for RNA-sequencing
776 and microarray studies. *Nucleic Acids Res* **43**, e47 (2015).
- 777 50. Peters, T.J. *et al.* De novo identification of differentially methylated regions in the human
778 genome. *Epigenetics Chromatin* **8**, 6 (2015).
- 779 51. Willer, C.J., Li, Y. & Abecasis, G.R. METAL: fast and efficient meta-analysis of
780 genomewide association scans. *Bioinformatics* **26**, 2190-1 (2010).
- 781 52. Matthew Suderman *et al.* dmrff: identifying differentially methylated regions efficiently
782 with power and control. (2022).
- 783 53. Perez-Enciso, M. & Tenenhaus, M. Prediction of clinical outcome with microarray data:
784 a partial least squares discriminant analysis (PLS-DA) approach. *Hum Genet* **112**, 581-92
785 (2003).
- 786 54. Donoho, D. De-noising by soft-thresholding. in *IEEE Transactions on Information*
787 *Theory*, Vol. 41 (1995).
- 788 55. Love, M.I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion
789 for RNA-seq data with DESeq2. *Genome Biol* **15**, 550 (2014).
- 790 56. Finotello, F. *et al.* Molecular and pharmacological modulators of the tumor immune
791 contexture revealed by deconvolution of RNA-seq data. *Genome Med* **11**, 34 (2019).
- 792 57. Chen, E.Y. *et al.* Enrichr: interactive and collaborative HTML5 gene list enrichment
793 analysis tool. *BMC Bioinformatics* **14**, 128 (2013).
- 794 58. Kuleshov, M.V. *et al.* Enrichr: a comprehensive gene set enrichment analysis web server
795 2016 update. *Nucleic Acids Res* **44**, W90-7 (2016).
- 796 59. Phipson, B., Maksimovic, J. & Oshlack, A. missMethyl: an R package for analyzing data
797 from Illumina's HumanMethylation450 platform. *Bioinformatics* **32**, 286-8 (2016).
- 798 60. Le Cao, K.A., Boitard, S. & Besse, P. Sparse PLS discriminant analysis: biologically
799 relevant feature selection and graphical displays for multiclass problems. *BMC*
800 *Bioinformatics* **12**, 253 (2011).

- 801 61. Tibshirani, R. Regression Shrinkage and Selection via the Lasso. *Journal of the Royal*
802 *Statistical Society* **58**, 267-288 (1996).
- 803 62. Singh, A. *et al.* DIABLO: an integrative approach for identifying key molecular drivers
804 from multi-omics assays. *Bioinformatics* **35**, 3055-3062 (2019).
- 805 63. Rohart, F., Gautier, B., Singh, A. & Le Cao, K.A. mixOmics: An R package for 'omics
806 feature selection and multiple data integration. *PLoS Comput Biol* **13**, e1005752 (2017).
- 807 64. Tarazona, S. *et al.* Harmonization of quality metrics and power calculation in multi-omic
808 studies. *Nature Communications* **11**, 3092 (2020).
- 809 65. Terry Therneau, P.G. *Modeling Survival Data: Extending the Cox Model*, (Springer, New
810 York, 2000).
- 811 66. Wickham, H. *ggplot2: Elegant graphics for data analysis*, (Springer-Verlag New York,
812 2009).
- 813 67. Cahais, V., Ghantous, A. & Zdenko, H. IARC pipeline for methylome analysis. (Zenodo,
814 2022).
- 815

816 **Acknowledgements**

817 We thank all melanoma patients who contributed to the study. This work was supported by Public
818 Ministry of Labor, Campinas (Research, Prevention, and Education of Occupational Cancer),
819 Barretos Cancer Hospital and International Agency for Research on Cancer. A.L.S.A.V. was
820 supported by FAPESP (grant no 2016/15941-3 and 2017/09612-0). We thank the BCH biobank
821 for DNA isolation and sample processing and storage. The initial development of the multi-OMICs
822 driver score was partially supported by the grant from the Institut National du Cancer (INCa,
823 France), La direction générale de l'offre de soins (DGOS), and INSERM (SIRIC LYriCAN, INCa-
824 DGOS-Inserm_12563) to Z.H.

825

826 **Author contributions**

827 Conceptualization: A.L.S.A.V., V.L.V. and A.G. Patient recruitment and clinical data collection in
828 BCH: C.S.C., A.L.C and V.L.V. Methylome array design: A.L.S.A.V. and A.G. Generation of array
829 and pyrosequencing methylation data: C.C. Analysis of OMICs data: A.L.S.A.V., A.N., V.C., Z.A.,
830 N.S., A.F.E. and A.G. Data interpretation: A.L.S.A.V., Z.H., R.M.R., V.L.V. and A.G. Supervision:
831 A.G., Z.H. and V.L.V. Writing original draft: A.L.S.A.V., V.L.V. and A.G. Editing and reviewing the
832 manuscript: all authors.

833

834 **Competing interests**

835 The authors declare no competing interests.

836 **Disclaimer**

837 Where authors are identified as personnel of the International Agency for Research on Cancer/
838 World Health Organization, the authors alone are responsible for the views expressed in this
839 article and they do not necessarily represent the decisions, policy or views of the International
840 Agency for Research on Cancer/ World Health Organization.

Table 1: Clinicopathological characteristics of the BCH-cutaneous melanoma patients, TCGA-cutaneous melanoma patients and BCH-acral melanoma patients profiled with the DNA methylation array.

Characteristics	Cutaneous BCH (Discovery cohort 1)	Cutaneous TCGA (Discovery cohort 2)	Acral BCH (Discovery cohort 3)
	No. of patients (%)	No. of patients (%)	No. of patients (%)
Gender			
Male	33 (61.1)	31 (53.4)	13 (61.9)
Female	21 (38.9)	27 (46.6)	8 (38.1)
Skin ^{§§§}			
White	51 (94.4)	58 (100.0)	15 (71.4)
Pigmented	3 (5.6)	0 (0.0)	6 (28.6)
Tumor type ^{**}			
Primary	20 (37.0)	9 (15.5)	13 (61.9)
Superficial spreading	13 (65.0)	Missing	Not applicable
Nodular	7 (35.0)	Missing	Not applicable
Metastatic	34 (63.0)	49 (84.5)	8 (38.1)
Superficial spreading	16 (47.1)	Missing	Not applicable
Nodular	8 (23.5)	Missing	Not applicable
Missing	10 (29.4)	Missing	Not applicable
Breslow depth (mm)			
Up to 1.0	5 (9.2)	5 (8.6)	2 (9.5)
1.1-2.0	7 (13.0)	14 (24.1)	2 (9.5)
2.1-4.0	9 (16.7)	9 (15.5)	3 (14.3)
More than 4.0	22 (40.7)	15 (25.9)	14 (66.7)
Missing	11 (20.4)	15 (25.9)	
TNM stage [*]			
in situ	0 (0.0)	0 (0.0)	0 (0.0)
I	7 (13.0)	8 (13.8)	1 (4.8)
II	16 (29.6)	18 (31.0)	8 (38.1)
III	14 (25.9)	19 (32.8)	10 (47.6)
IV	15 (27.8)	2 (3.4)	2 (9.5)
Missing	2 (3.7)	11 (18.0)	
UV signature ^{§§§}			
No	10 (18.5)	11 (19.0)	17 (81.0)
Yes	44 (81.5)	47 (81.0)	4 (19.0)
Molecular group ^{**§§§}			
BRAF	39 (72.2)	23 (39.7)	4 (19.0)
RAS	6 (11.1)	20 (34.5)	6 (28.6)
NF1	2 (3.7)	6 (10.3)	1 (4.8)
TN	7 (13.0)	9 (15.5)	10 (47.6)
Age [Mean (SD)]	57.3 (17.0)	57.7 (14.7)	59.4 (12.5)

*Variables statistically different between BCH-cutaneous and TCGA-cutaneous melanoma patients using two-sided Chi-square test. §Variables statistically different between BCH-cutaneous and BCH-acral melanoma patients using Chi-square test. *, §p < 0.05, **, §§p < 0.01 and ***, §§§p < 0.001.




Figure 1: Study design, resources and methodology. A major aim (steps 1-2) is the discovery and validation of genome-wide methylation alterations associated with the UV mutational signature in cutaneous melanoma, based on two independent cohorts. Another major aim (step 3) is assessing the discriminative potential of the DNA methylome *versus* transcriptome *versus* integrated methylome-transcriptome in differentiating between UV-mutant and non UV-mutant cutaneous melanomas. The integrative OMICs approach is expanded to include small nucleotide variants (SNVs) and copy number variants (CNVs) in order to assess cancer driver potential of prioritized differentially methylated genes. This is complemented by step 4, which investigates whether the DNA methylome could capture pathological and/or UV-related differences between major melanoma types predominantly associated with UV exposure (cutaneous melanoma) and those not (acral melanoma).




Figure 2: Cross genome-methylome analysis of UV mutation signatures in cutaneous melanoma patients from BCH and TCGA cohorts. a) Kaplan–Meier survival curves of melanoma patients by UV signature status in BCH (n= 50) and TCGA (n= 52). The P-values were derived by log-rank test. Also shown are the DMR distributions from the crude model relative to chromosomal location (b), genomic regulatory regions (c), and CpG density regions (d) in both BCH (n=54) and TCGA (n=58). Enrichment analysis of hyper- and hypo-methylated DMRs relative to the 450K reference set in (c) and (d) was done using two-sided Chi-square test. *** p< 0.001.




Figure 3: The DNA methylome marks UV exposure and associated *BRAF/RAS/NF1* mutations, with effect on immunomodulation. a) Hierarchical clustering of cutaneous melanoma patients in BCH and TCGA based on methylation levels of 4,721 and 793 CpGs, respectively, as derived from Supplementary Fig. 1a. Enrichment analysis for non UV-mutant patients in clusters C1-C4 was performed using two-sided Chi-square test while delimiting the cluster boundaries by the limits statistically specified by Euclidean distance. b) Proportions of *BRAF*, *NF1*, *RAS* and *TN* groups in UV-mutant and non UV-mutant melanomas. P-values were derived by two-sided Fisher's exact test. c) Common KEGG pathways between BCH and TCGA of genes differentially methylated between UV-mutant and non UV-mutant cutaneous melanoma patients, as derived from the prioritized CpGs in Supplementary Fig. 1a. Solid lines around the pathways' names indicate those with $FDR < 0.05$ in BCH and/or TCGA; whereas, dashed lines indicate those with $p < 0.05$. The percentage represents the average effect size across the CpGs of a given gene. Genes written in black are common between BCH and TCGA; whereas, green ones were found only in BCH and purple ones only in TCGA. †Pathways significant after adjustment for the number of CpGs associated with each gene. P-value was delivered from two-sided Fisher exact test. d) Immune cell composition inferred from RNA sequencing data comparing UV-mutant ($n = 47$) and non UV-mutant ($n = 11$) cutaneous melanoma patients from TCGA. Box center lines, bound of the box, and whiskers indicate medians, first and third quantiles, and minimum and maximum values within $1.5 \times IQR$ (interquartile range) of the box limits, respectively. Each data point in the box plot represents the samples. * $p < 0.05$, by two-sided Mann-Whitney U Test.




Figure 4: UV-related DNA methylome-wide alterations common between BCH and TCGA are prognostic for survival in cutaneous melanoma patients. a) Venn diagrams showing that DMR-derived 169 genes or 458 CpGs are common between BCH and TCGA, based on the crude model. b) DMR fixed effects inverse variance-weighted meta-analysis of BCH and TCGA, and comparison with the cohort-specific analysis. c) Kaplan-Meier survival of melanoma patients in relation to methylation levels of cg18930100 (*TAPBP*) measured in the target tumors derived from BCH and TCGA. Patients were categorized into low- and high-methylation groups depending on whether the methylation value of a given CpG is lower or higher, respectively, than the mean methylation across the samples profiled for that CpG. P-values were derived by two-sided log-rank test. d) DNA methylation profiles of cg18930100 (*TAPBP*) that is associated with melanoma-specific survival, showing differential methylation between UV-mutant (n= 44 and 47 in BCH and TCGA, respectively) and non UV-mutant patients (n= 10 and 11 in BCH and TCGA, respectively). Data were expressed as the average values of each group (UV-mutant and non UV-mutant) for each single CpG with error bars indicating the 95% confidence interval (CI).




Figure 5: Validation, eQTM and multi-OMICs cancer driver analysis of UV methylome markers. a) Pearson correlation was used to measure linear relationships between DNA methylation (Beta values) and gene expression levels measured in the same samples for the 10 selected CpGs (filtration step described in Supplementary Fig. 1a), using the TCGA dataset (UV-mutant= 11 and non UV-mutant= 47). Box center lines, bound of the box, and whiskers indicate medians, first and third quantiles, and minimum and maximum values within 1.5xIQR (interquartile range) of the box limits, respectively. Each data point in the box plot represents the samples. The correlation r and P-values were calculated by the two-sided correlation test and are shown for each CpG. b) Multi-OMICs data integration from TCGA, encompassing copy number variation (CNV), expression (EXP), methylation (METH) and mutation (MUT), was performed in order to decipher the driver potential of the 12 prioritized genes (see Results) in cutaneous melanoma development following UV exposure. For each gene, scores of CNV, MUT, EXP, METH and multi-OMICs driver are indicated in the table and plotted in the associated circular diagram. c) Validation of array-based DNA methylation by bisulfite pyrosequencing of the *TAPBP* gene in BCH samples (UV-mutant= 10 and non UV-mutant= 44). Data were expressed as the average values of each group (UV-mutant and non UV-mutant) for each single CpG with error bars indicating the 95% confidence interval.




Figure 6: Comparative maps of the DNA methylome and transcriptome of cutaneous and acral melanomas in relation to UV mutational signatures, with associated patient survival and biological pathways. a) PLS-DA modeling based on DNA methylome (left panel) or transcriptome (right panel) data derived from UV-mutant and non UV-mutant cutaneous melanoma from TCGA. b) Diablo integrative analysis method with LASSO penalization were applied on methylome and transcriptome data from TCGA to select the most informative CpGs and transcripts that could improve the classification of the UV-mutant and non UV-mutant cutaneous melanomas. c) Methylome matrices of acral (excluding the few UV-mutants), UV-mutant and non UV-mutant cutaneous melanomas based on the 100 most variables CpGs selected using median absolute deviation (MAD) and analysed with Partial Least Squares Discriminant Analysis (PLS-DA) in the BCH samples. d) Melanoma-specific survival comparing the three groups of melanoma patients: cutaneous UV-mutant, cutaneous non UV-mutant and acral non UV-mutant. P-value was delivered from log rank test. e) KEGG pathways of genes differentially methylated between acral *versus* cutaneous non UV-mutant melanomas in BCH, as derived from the prioritized CpGs in Supplementary Fig. 2a. Dashed lines around the pathways' names indicate those with $p < 0.05$; none were FDR-significant. The percentage represents the average effect size across the CpGs of a given gene. †Pathways significant after adjustment for the number of CpGs associated with each gene.